UNH
63
-2
DGX
48
-3
PLD
56
8
CNP
50
-2
BAX
27
-2
UHS
54
-4
VNO
60
8
FLS
76
-2
NTAP
61
-3
MS
80
-3
GLW
48
-5
FDX
54
14
EQR
60
6
QRVO
4
-2
MMM
42
5
LOW
58
2
SIG
47
-2
PSA
58
5
TRV
56
-2
CI
52
-7
UNH
63
-2
DGX
48
-3
PLD
56
8
CNP
50
-2
BAX
27
-2
UHS
54
-4
VNO
60
8
FLS
76
-2
NTAP
61
-3
MS
80
-3
GLW
48
-5
FDX
54
14
EQR
60
6
QRVO
4
-2
MMM
42
5
LOW
58
2
SIG
47
-2
PSA
58
5
TRV
56
-2
CI
52
-7
Financhill
Back

Syros Pharmaceuticals 10K Form

Sell
33

SYRS
Syros Pharmaceuticals

Last Price:
0.32
Seasonality Move:
17.91%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive SYRS News And Ratings

See the #1 stock for the next 7 days that we like better than SYRS

SYRS Financial Statistics

Sales & Book Value

Annual Sales: $9.94M
Cash Flow: $-20.69M
Price / Cash Flow: 0
Annual Sales: $-0.41
Price / Book: 0

Profitability

EPS (TTM): -3.07000
Net Income (TTM): $-97.82M
Gross Margin: --
Return on Equity: 0%
Return on Assets: 0%

Syros Pharmaceuticals Earnings Forecast

Key Syros Pharmaceuticals Financial Ratios

  • The Research & Development expenses have been 1,088.50% of Revenue.
  • The Interest Expense is -3.12% of Operating Income.
  • The Net Earning history of SYRS is -1,656.34% of Total Revenues.
  • Per Share Earnings over the last 10 years have been positive in 8 years.

Syros Pharmaceuticals Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: SYRS
CUSIP: 87184Q
Website: syros.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 0
Quick Ratio: 0

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

SYRS Technical Analysis vs Fundamental Analysis

Sell
33
Syros Pharmaceuticals (SYRS) is a Sell

Is Syros Pharmaceuticals a Buy or a Sell?